STING-IN-17

• Description :

  STING-IN-17 is an orally active STING (human STING IC50 = 29 nM, mouse STING IC50 = 15 nM) inhibitor. STING-IN-17 can inhibit the phosphorylation of STING, TBK1 and IRF3. STING-IN-17 dose dependently inhibits the mRNA expression of IP10, IFNB1 and ISG56. STING-IN-17 can reduce ROS and inhibit the expression of cleaved-PARP/caspase-3. STING-IN-17 can improve kidney function. STING-IN-17 can be used for research on inflammatory conditions such as acute kidney injury[1].

• CAS Number :

  [3069635-58-8]

• UNSPSC :

  12352005

• Target :

  Caspase; IFNAR; IKK; PARP; Reactive Oxygen Species (ROS) ; STING

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Inflammation/Immunology

• Smiles :

  O=C(C1=CC=C(C(C)(C)C(N2CC3CN(C4=CC(C(F)(F)F)=CC(F)=C4)C3)=O)C2=C1)NC5=CNC6=C5C=CC=C6

• Molecular Formula :

  C30H26F4N4O2

• Molecular Weight :

  550.55

• References & Citations :

  [1]Li W, et al. Discovery of a potent and orally bioavailable 3,3-dimethyl-2-oxoindoline STING inhibitor. Eur J Med Chem. 2026 Jan 5;301:118232.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  Caspase 3; TBK1